Solventum Corporation (BST:KB7)
Germany · Delayed Price · Currency is EUR | Market Cap | 13.27B +22.8% |
| Revenue (ttm) | 7.27B -0.9% |
| Net Income | 1.26B +277.4% |
| EPS | 7.17 +275.1% |
| Shares Out | n/a |
| PE Ratio | 10.57 |
| Forward PE | 12.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 76.00 |
| Previous Close | 76.80 |
| Day's Range | 76.00 - 78.60 |
| 52-Week Range | 53.60 - 80.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Solventum
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tap... [Read more]
Financial Performance
In 2025, Solventum's revenue was $8.33 billion, an increase of 0.86% compared to the previous year's $8.25 billion. Earnings were $1.56 billion, an increase of 224.84%.
Financial numbers in USD Financial StatementsNews
Solventum Transcript: Wells Fargo 21st Annual Healthcare Conference
Revised summary: Management confirmed the HIS separation is for strategic focus on medtech, with RemainCo’s 4%-5% organic growth target by 2028 intact. Margin dilution is expected, but operational efficiencies, new product launches, and growth in MedSurg and Dental support margin and EPS expansion. Nearly 20 new products are planned through Q1 2028.
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
EAGAN, Minn., Sept. 2, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept.
Solventum to hive off healthcare software business, raises profit forecast
Solventum , one of the largest providers of hospital consumables and sterilization devices, said on Wednesday it is planning to separate its health information systems business as part of its ongoin...
Solventum Earnings Call Transcript: Q2 2026
Q2 results exceeded expectations with strong organic growth, margin expansion, and robust performance across all segments. Guidance for 2026 was raised, reflecting confidence in continued growth, successful transformation progress, and the planned HIS separation to unlock value.
Solventum Earnings release: Q2 2026
Solventum released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Solventum Slides: Q2 2026
Solventum has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Solventum Quarterly report: Q2 2026
Solventum has published its Q2 2026 quarterly earnings report on August 5, 2026.
Solventum Shareholder letter: Q2 2026
Solventum has published a letter to shareholders covering Q2 2026, which was released on August 5, 2026.
Solventum Reports Second Quarter 2026 Financial Results
Reported sales increased 2.2%; organic sales increased 9.5% Announces intent to separate its Health Information Systems business segment Increases full-year 2026 guidance for organic sales growth, adj...
Solventum Announces Intent to Separate its Health Information Systems Business
Strengthens the focus of Solventum as a dedicated MedTech company and advances its three-phase transformation strategy Positions Health Information Systems, a leading, scaled, healthcare software busi...
Solventum to Report Second Quarter Fiscal 2026 Earnings on August 5, 2026
EAGAN, Minn., July 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its second quarter fiscal 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close.
Solventum Transcript: Jefferies Global Healthcare Conference 2026
The business is executing a three-phase transformation, focusing on innovation, portfolio optimization, and margin expansion. Strong Q1 results support higher-end EPS guidance, with ongoing product launches and AI integration driving growth. Capital allocation balances tuck-in M&A and share repurchases.
Solventum to Participate in the 2026 Jefferies Healthcare Conference
EAGAN, Minn., May 27, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, Jun. 3, 2026,...
Solventum Transcript: AGM 2026
Shareholders elected Class II directors, approved executive compensation, and ratified PwC as auditors with strong majorities. Quorum and proper notice were confirmed, and Q&A responses will be posted online.
Solventum Transcript: Bank of America Global Healthcare Conference 2026
Health Information Systems is experiencing accelerated growth through AI-driven automation, international expansion, and deep U.S. market penetration, with over 75% of hospitals using its products. The business maintains high margins, leverages proprietary rules for accuracy, and expects stable performance despite ERP-driven sales timing shifts.
Solventum to Participate in the 2026 BofA Securities Health Care Conference
ST. PAUL, Minn., May 7, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the BofA Securities Health Care Conference on Wednesday, May ...
Solventum forecasts annual profit at higher end on wound care demand
Medical device maker Solventum said on Tuesday it expects annual profit to be at the higher end of its previous forecast range, primarily driven by strong demand for its wound care and sterilization...
Solventum Earnings Call Transcript: Q1 2026
Q1 fiscal 2026 results exceeded expectations, with strong organic sales growth, margin expansion, and EPS outperformance. Transformation initiatives, portfolio optimization, and new product launches are driving momentum, while guidance for the year is maintained with EPS now expected at the high end of the range.
Solventum Earnings release: Q1 2026
Solventum released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Solventum Slides: Q1 2026
Solventum has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Solventum Quarterly report: Q1 2026
Solventum has published its Q1 2026 quarterly earnings report on May 5, 2026.
Solventum Shareholder letter: Q1 2026
Solventum has published a letter to shareholders covering Q1 2026, which was released on May 5, 2026.
Solventum Reports First Quarter 2026 Financial Results
Reported sales decreased (3.0)%; organic sales increased 2.1% Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing ra...
Peltz's Trian urges Solventum to rightsize costs, divest non-core businesses
Nelson Peltz's Trian Fund Management on Thursday called on Solventum to rightsize overhead costs, divest non-core businesses and improve capital allocation in its latest appeal for a performance tur...
Trian Calls on Solventum's Board to Create Value; Publishes Open Letter and Slide Deck
Solventum's Spin-Out from 3M has Maximized Executive Compensation, Not Shareholder Value Outlines Three Initiatives to Improve Performance and Drive Value Creation at Solventum NEW YORK, April 30, 202...